Physician profile
Mark A Nelson
NPI 1922084409
$13,325.39
in general payments reported to CMS, 2019-2025
69 companies · $2,705 in 2025
The $2,705 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,694 · 2020: $1,207 · 2021: $1,402 · 2022: $1,638 · 2023: $2,002 · 2024: $2,678 · 2025: $2,705.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,372 · Education: $12.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,372.05 |
| Education | $12.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,757.54 | 2021-2025 | |
| Biogen, INC. | $942.44 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $692.14 | 2019-2025 | Zilbrysq, Rystiggo, Fintepla |
| Neurocrine Biosciences, INC. | $601.60 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $578.90 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $573.61 | 2019-2025 | |
| Lilly USA, LLC | $489.25 | 2019-2025 | Emgality, Reyvow, Kisunla |
| Amgen INC. | $471.09 | 2019-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $467.23 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $435.78 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $395.05 | 2021-2024 | Acthar |
| Supernus Pharmaceuticals, INC. | $367.20 | 2019-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $330.77 | 2020-2025 | Vyepti, Rexulti |
| Argenx US, INC. | $314.81 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Pfizer INC. | $268.17 | 2023-2025 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.